Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

No Link Between Race and Renal Toxicity in Treatment of NS-NSCLC

November 3, 2021
By Nino Balanchivadze, MD, FACP
Video

Nino Balanchivadze, MD, FACP, discusses the results of an analysis investigating renal toxicity in patients with nonsquamous non–small cell lung cancer in relation to the race of patients.

Nino Balanchivadze, MD, FACP, senior administrative fellow of the Hematology and Oncology Fellowship Program at Henry Ford Cancer Institute, discusses the results of an analysis investigating renal toxicity in patients with nonsquamous non–small cell lung cancer treated in the KEYNOTE-189 study (NCT02578680).

The retrospective analysis looked at acute kidney injury (AKI) as an adverse event of pemetrexed (Alimta) combined with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-189 clinical trial. Though Black Americans have previously been found to be at a higher risk of morbidity and mortality from chronic kidney disease (CKD), the study found no correlation between AKI in Black patients compared with White patients.

The study, recently presented during the 2021 European Society for Medical Oncology Annual Congress, analyzed a total of 134 patients, 33 of whom (24.6%) identified as non-Hispanic Black, and 101 (75.4%) who identified as non-Hispanic White. The mean age of patients was 66.5 years. Investigators observed that 8.1% of patients developed AKI, with a median time to development of 4.5 months.

Of the 10 patients who experienced AKI, 3 were Black and 7 were White (P = .57), showing no correlation between race and AKI development.

The median overall survival of all patients was 15.2 months. Black ethnicity was not associated with increased mortality in this patient population (HR, 1.21; P = .46), and development of AKI was also not associated with increased mortality (HR, 1.13; 95% CI, 0.45-2.86).

Other conditions such as hypertension, diabetes mellitus, cardiovascular disease, or CKD were not associated with AKI in these patients. However, patients with CKD were more likely to have a reduced glomerular filtration rate (GFR).

0:08 | We found we had a total of 134 patients that were included in the analysis. The mean age of patients was 66.5 years, and about 48.5% patients were men. A total of 33 patients, or 24.6% of our patients were non-Hispanic Black, and 75.4% of patients were non-Hispanic White. There were 10 patients who developed AKI and with the median time to development of kidney injury was 4.5 [months], with no margin of [patients of] black or white race with AKI. And the odds of developing AKI was not increased in patients with a history of hypertension, diabetes mellitus, cardiovascular disease, or CKD. We also found that a total of 17, or 13.4% of patients, had significantly reduced GFR, and patients that had a history of CKD were more likely to have reduced GFR.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC

Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC

Targeted Oncology Staff
June 19th 2025
Article

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of single agent vs doublet immunotherapy in the PD-L1–low setting.

Read More


Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Jordyn Sava;Aaron Lisberg, MD
December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen


Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Jordyn Sava
June 19th 2025
Article

Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.

Read More


Strategies for Neoadjuvant NSCLC Treatment

Strategies for Neoadjuvant NSCLC Treatment

Nichole Tucker;Benny Weskler, MBA, MD, FACS, FACCP
September 1st 2023
Podcast

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Listen


Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Sabrina Serani
June 16th 2025
Article

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Read More

Related Content

Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC

Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC

Targeted Oncology Staff
June 19th 2025
Article

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of single agent vs doublet immunotherapy in the PD-L1–low setting.

Read More


Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Jordyn Sava;Aaron Lisberg, MD
December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen


Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Jordyn Sava
June 19th 2025
Article

Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.

Read More


Strategies for Neoadjuvant NSCLC Treatment

Strategies for Neoadjuvant NSCLC Treatment

Nichole Tucker;Benny Weskler, MBA, MD, FACS, FACCP
September 1st 2023
Podcast

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Listen


Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Sabrina Serani
June 16th 2025
Article

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.